SG11201700061PA - Viral prophylaxis treatment methods and pre-exposure prophylaxis kits - Google Patents

Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Info

Publication number
SG11201700061PA
SG11201700061PA SG11201700061PA SG11201700061PA SG11201700061PA SG 11201700061P A SG11201700061P A SG 11201700061PA SG 11201700061P A SG11201700061P A SG 11201700061PA SG 11201700061P A SG11201700061P A SG 11201700061PA SG 11201700061P A SG11201700061P A SG 11201700061PA
Authority
SG
Singapore
Prior art keywords
prophylaxis
kits
treatment methods
viral
exposure
Prior art date
Application number
SG11201700061PA
Other languages
English (en)
Inventor
Emidio A Checcone
Christina Ramirez
Original Assignee
Prophylaxis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophylaxis LLC filed Critical Prophylaxis LLC
Publication of SG11201700061PA publication Critical patent/SG11201700061PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201700061PA 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits SG11201700061PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021589P 2014-07-07 2014-07-07
PCT/US2015/039421 WO2016007538A1 (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Publications (1)

Publication Number Publication Date
SG11201700061PA true SG11201700061PA (en) 2017-02-27

Family

ID=55016233

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700061PA SG11201700061PA (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
SG10201913641XA SG10201913641XA (en) 2014-07-07 2015-07-07 Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913641XA SG10201913641XA (en) 2014-07-07 2015-07-07 Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits

Country Status (15)

Country Link
US (1) US10052329B2 (he)
EP (2) EP3166680B1 (he)
JP (3) JP7525976B2 (he)
KR (2) KR20240110074A (he)
CN (2) CN106794336B (he)
AU (3) AU2015287994B2 (he)
BR (1) BR112017000285A2 (he)
CA (1) CA2954526C (he)
ES (1) ES2964529T3 (he)
IL (2) IL249938B (he)
MX (1) MX2017000059A (he)
NZ (2) NZ728045A (he)
PL (1) PL3166680T3 (he)
SG (2) SG11201700061PA (he)
WO (1) WO2016007538A1 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201700061PA (en) 2014-07-07 2017-02-27 Prophylaxis LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US11071745B2 (en) * 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US10918623B2 (en) * 2017-02-08 2021-02-16 Biotron Limited Methods of treating influenza
KR102666078B1 (ko) * 2017-06-28 2024-05-20 아이쿠리스 게엠베하 운트 코. 카게 항바이러스성 화합물을 포함하는 질내 적용 가능한 장치
MX2021004553A (es) * 2018-10-23 2021-07-16 Eastern Virginia Medical School Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2020092990A1 (en) * 2018-11-02 2020-05-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
CA3131159A1 (en) 2019-02-25 2020-09-03 Elian Llc Treatment of herpes simplex with a combination of valacyclovir and famciclovir
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN114929212A (zh) * 2019-10-29 2022-08-19 传明科技有限责任公司 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合
US20210322469A1 (en) * 2020-04-20 2021-10-21 Regents Of The University Of Minnesota Zinc and copper for the prophylaxis and treatment of covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
JP4665075B2 (ja) 1998-04-21 2011-04-06 ユニベルシテ ラバル 粘膜または皮膚を冒す疾病の防止または治療のための、または妊娠の防止のための製剤、および、粘膜腔内に局所用製剤を到達させるためのアプリケーター
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP5322918B2 (ja) 2006-03-22 2013-10-23 スターファーマ・プロプライエタリー・リミテッド 避妊用組成物
US8946243B2 (en) 2008-03-28 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the treatment of viral infection
US8853223B2 (en) * 2010-09-17 2014-10-07 G2L Touch, Inc. Therapeutic composition to treat lesions caused by herpes simplex virus
WO2011156416A1 (en) 2010-06-11 2011-12-15 Gilead Sciences, Inc. Topical antiviral formulations for prevention of transmission of hsv-2
US9155873B2 (en) 2011-05-17 2015-10-13 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
JP6170044B2 (ja) * 2011-07-20 2017-07-26 エフ． カイザー，パトリック 薬物送達のための膣内デバイス
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
SG11201700061PA (en) 2014-07-07 2017-02-27 Prophylaxis LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Also Published As

Publication number Publication date
EP3166680A1 (en) 2017-05-17
MX2017000059A (es) 2017-11-08
AU2015287994B2 (en) 2020-03-12
JP2017527610A (ja) 2017-09-21
US20160000797A1 (en) 2016-01-07
AU2022275517A1 (en) 2023-01-05
AU2020203896A1 (en) 2020-07-02
PL3166680T3 (pl) 2024-03-25
JP7525976B2 (ja) 2024-07-31
EP4342545A2 (en) 2024-03-27
IL273932A (he) 2020-05-31
AU2020203896B2 (en) 2022-08-25
BR112017000285A2 (pt) 2017-10-31
CN114469958A (zh) 2022-05-13
CA2954526A1 (en) 2016-01-14
KR20240110074A (ko) 2024-07-12
JP2023179575A (ja) 2023-12-19
NZ728045A (en) 2024-08-30
IL249938B (he) 2020-04-30
EP3166680C0 (en) 2023-11-15
US10052329B2 (en) 2018-08-21
IL249938A0 (he) 2017-03-30
ES2964529T3 (es) 2024-04-08
IL273932B1 (he) 2023-03-01
IL273932B2 (he) 2023-07-01
EP3166680A4 (en) 2018-01-17
EP3166680B1 (en) 2023-11-15
KR20170063512A (ko) 2017-06-08
CN106794336B (zh) 2022-01-11
CA2954526C (en) 2023-03-07
WO2016007538A1 (en) 2016-01-14
SG10201913641XA (en) 2020-03-30
CN106794336A (zh) 2017-05-31
AU2015287994A1 (en) 2017-02-02
EP4342545A3 (en) 2024-06-26
NZ765819A (en) 2024-08-30
JP2021138723A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
HK1258795A1 (zh) 絲狀病毒科病毒感染的治療方法
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
HK1252937A1 (zh) 用於治療抑鬱症的方法和試劑盒
IL249938A0 (he) שיטות וערכות לטיפול מונע בטרם חשיפה להדבקה ויראלית
GB201701673D0 (en) Methods of well treatment
EP3229906C0 (en) SYSTEMS AND METHODS FOR OPTIMIZING TRANSCRANIAL ACOUSTIC TREATMENT
IL248803A0 (he) אמצעים ושיטות לטיפול ב- cmv
IL251759B (he) תכשירים ושיטות לטיפול בנדודי שינה
EP3174475C0 (en) CATHETER DEVICES AND KITS
EP3133919A4 (en) Agents and methods for treatment of pathogens
IL251885A0 (he) חיידקים מייצרים נוסקפינואיד ושיטות להכנתם ושימוש בהם
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
IL246643B (he) תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת
GB201402909D0 (en) Treating infection
GB201417372D0 (en) Methods and kits
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
EP3215180A4 (en) Methods and kits for treating cardiovascular diseases
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201421904D0 (en) Methods and kits
GB201509908D0 (en) Methods and kits
AU2014902732A0 (en) Treatment and prophylaxis
AU2014901470A0 (en) Agents and methods for treatment of pathogens